Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2013 Jul 26;12(10):2200–2212. doi: 10.1158/1535-7163.MCT-13-0095

Figure 4.

Figure 4

Treatment of cells with niclosamide blocks erlotinib-induced activation of STAT3/Bcl2/Bcl-XL and reverses erlotinib resistance. A, HCC827 and HCC827/ER cells were treated with erlotinib (Erlo, 0.1 μM) in the absence or presence of increasing concentrations of niclosamide (Niclo) for 48h. pSTAT3, Bcl2, Bcl-XL and Mcl-1 were analyzed by Western Blot. B, HCC827 and HCC827/ER cells were treated with various concentrations of erlotinib (Erlo), niclosamide (Niclo, 0.5 μM) or their combination for 48 h. Cell growth was evaluated by SRB assay.